Neo-adjuvant Pembrolizumab as an Alternative Treatment for MMRd Uterine Cancer
Status:
Recruiting
Trial end date:
2028-01-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to establish the fraction of patients that achieve a major
pathological response (MPR) after 9 cycles of pembrolizumab, with the ultimate aim of
informing a follow-up randomized trial.
Participants will receive 9 cycles of pembrolizumab before their standard of care
hysterectomy.